Professor Cha Jae-myung of Gangdong Kyunghee University Hospital selected the winner of the distinguished researcher award and achievement award of the Korean Intestinal Research Society
Mar 19, 2025
Cha Jae-myung, a professor of gastroenterology at Gangdong Kyunghee University Hospital, has been selected as the winner of the 'Excellent Researcher Award' and 'Excellence Award' at IMKASID 2025, an international academic conference of the Korean Intestinal Research Society scheduled to be held in April this year.
IMKASID 2025(The 8th International Meeting on Intestinal Diseases in conjunction with the Annual Congress of the Korean Association for the Study of Intestinal Diseases)는 대한장연구학회에서 매년 개최하는 국제학술대회다. This year, it will be held for three days from April 10-12 at the Grand Walkerhill Hotel in Seoul.
IMKASID 2025 is a conference involving officials from all over the world, and in 2024, more than 970 prominent researchers and officials from 27 countries, including the Americas and Europe, attended. It has become the best place for exchange in the field of intestinal disease that shares the latest knowledge in the basic and clinical research fields of each country and forms a global network beyond Asia.
The goal of this year's conference is set to 'explore, reinforce, and evolve the long journey of bowel disease research (The Intellectual Odyssey: Explore, Empower, and Evolve). On-site lectures by domestic and foreign scholars will be held on the latest knowledge in the fields of inflammatory bowel disease, colon tumors, colon and small intestine endoscopy, nutrition and microbiome, including basic and clinical areas.
Professor Cha Jae-myung, who is leading research in the field of intestinal disease in Korea, will also play an active role in the IMKASID2025 event. First, we will receive the 'Distinguished Investigator Awards' presented to researchers with outstanding research achievements.
He was recognized for his contribution to pioneering a new market for intestinal cleansing drugs by serving as a clinical lead researcher for multi-center joint research on mini S-OST drugs, a pill to be taken among newly marketed intestinal cleansing drugs in Korea.
In addition, he was honored to receive the Contribution Award at the same time. The merit award is given to recognize and encourage domestic researchers who have made important contributions in the field of bowel disease. In addition, the conference will give a lecture on the advantages and disadvantages of the national colon cancer screening project based on colonoscopy, which is scheduled to be introduced in Korea.
IMKASID 2025(The 8th International Meeting on Intestinal Diseases in conjunction with the Annual Congress of the Korean Association for the Study of Intestinal Diseases)는 대한장연구학회에서 매년 개최하는 국제학술대회다. This year, it will be held for three days from April 10-12 at the Grand Walkerhill Hotel in Seoul.
IMKASID 2025 is a conference involving officials from all over the world, and in 2024, more than 970 prominent researchers and officials from 27 countries, including the Americas and Europe, attended. It has become the best place for exchange in the field of intestinal disease that shares the latest knowledge in the basic and clinical research fields of each country and forms a global network beyond Asia.
The goal of this year's conference is set to 'explore, reinforce, and evolve the long journey of bowel disease research (The Intellectual Odyssey: Explore, Empower, and Evolve). On-site lectures by domestic and foreign scholars will be held on the latest knowledge in the fields of inflammatory bowel disease, colon tumors, colon and small intestine endoscopy, nutrition and microbiome, including basic and clinical areas.
Professor Cha Jae-myung, who is leading research in the field of intestinal disease in Korea, will also play an active role in the IMKASID2025 event. First, we will receive the 'Distinguished Investigator Awards' presented to researchers with outstanding research achievements.
He was recognized for his contribution to pioneering a new market for intestinal cleansing drugs by serving as a clinical lead researcher for multi-center joint research on mini S-OST drugs, a pill to be taken among newly marketed intestinal cleansing drugs in Korea.
In addition, he was honored to receive the Contribution Award at the same time. The merit award is given to recognize and encourage domestic researchers who have made important contributions in the field of bowel disease. In addition, the conference will give a lecture on the advantages and disadvantages of the national colon cancer screening project based on colonoscopy, which is scheduled to be introduced in Korea.
|
This article was translated by Naver AI translator.
